Literature DB >> 20640598

Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5.

Ana de Lurdes Agostinho Cabrita1, Ana Pinho, Anabela Malho, Elsa Morgado, Marília Faísca, Hermínio Carrasqueira, Ana Paula Silva, Pedro Leão Neves.   

Abstract

BACKGROUND/AIMS: Anemia is common in patients with chronic kidney disease (CKD). Recently, the erythropoiesis-stimulating agent/hemoglobin level (ESA/Hb) index emerged as a new factor associated with increased morbidity and mortality in this population. In this study, we evaluated the factors that influence the ESA/Hb index in a pre-dialysis CKD population.
METHODS: Ninety-five patients were evaluated for clinical and laboratory parameters, nutritional status and ESA/Hb index. For comparison, we divided our population into 3 groups: G I--no ESA treatment, G II--patients with ESA/index below 50th percentile and G III--patients with ESA/Hb index above 50th percentile. We performed single and multiple regression models and logistic regression analysis.
RESULTS: In a multiple regression model, age (t = -3.456, P = 0.001), SGA (t = 2.059, P = 0.047), ferritin (t = 2.386, P = 0.027), Ca × P (t = 2.066, P = 0.043), TNF-α (t = 2.673, P = 0.009) and IL-6 (t = 2.939, P = 0.004) independently influenced the ESA/Hb index. At logistic regression analysis, gender, cardiovascular disease and TNF-α were independently associated with ESA/Hb higher than 50th percentile compared to the other patients (R(2) = 0.457).
CONCLUSION: In a pre-dialysis population, female gender, cardiovascular disease, malnutrition and inflammation are associated with a higher ESA/Hb index.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20640598     DOI: 10.1007/s11255-010-9805-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  43 in total

1.  Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts.

Authors:  Oluwatoyin Fatai Bamgbola; Fredrick J Kaskel; Maria Coco
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

2.  The elderly on dialysis: some considerations in compliance.

Authors:  P M McKevitt; J F Jones; D A Lane; R R Marion
Journal:  Am J Kidney Dis       Date:  1990-10       Impact factor: 8.860

3.  Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients.

Authors:  Dennis J Cotter; Kevin Stefanik; Yi Zhang; Mae Thamer; Daniel Scharfstein; James Kaufman
Journal:  J Clin Epidemiol       Date:  2004-10       Impact factor: 6.437

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  Low hemoglobin, chronic kidney disease, and risk for coronary heart disease-related death: the Blue Mountains Eye Study.

Authors:  Stephen R Leeder; Paul Mitchell; Gerald Liew; Elena Rochtchina; Wayne Smith; Jie Jin Wang
Journal:  J Am Soc Nephrol       Date:  2005-11-30       Impact factor: 10.121

6.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

Review 7.  Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management.

Authors:  Mehmet Kanbay; Mark A Perazella; Benan Kasapoglu; Mustafa Koroglu; Adrian Covic
Journal:  Blood Purif       Date:  2009-10-08       Impact factor: 2.614

Review 8.  Anaemia and inflammation: what are the implications for the nephrologist?

Authors:  Peter Stenvinkel
Journal:  Nephrol Dial Transplant       Date:  2003-11       Impact factor: 5.992

9.  Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis.

Authors:  Mingxin Wei; Joanne M Bargman; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2007-05-30       Impact factor: 2.370

10.  Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.

Authors:  C G Winearls; D O Oliver; M J Pippard; C Reid; M R Downing; P M Cotes
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

View more
  7 in total

1.  Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients.

Authors:  Michio Kuwahara; Youhei Arai; Eriko Takehara; Yasunori Sasaki; Tomoharu Yoshimine; Keita Kusaka; Satomi Shikuma; Wataru Akita; Shinichi Uchida
Journal:  Clin Exp Nephrol       Date:  2015-10-28       Impact factor: 2.801

2.  Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease.

Authors:  Michio Kuwahara; Shintaro Mandai; Yuri Kasagi; Keita Kusaka; Tomomi Tanaka; Satomi Shikuma; Wataru Akita
Journal:  Clin Exp Nephrol       Date:  2014-09-03       Impact factor: 2.801

3.  Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay.

Authors:  Rachel Gavish; Salmas Watad; Nathalie Ben-Califa; Ori Jacob Goldberg; Orly Haskin; Miriam Davidovits; Gili Koren; Yafa Falush; Drorit Neumann; Irit Krause
Journal:  Pediatr Nephrol       Date:  2018-07-20       Impact factor: 3.714

4.  Impact of gender and dialysis adequacy on anaemia in peritoneal dialysis.

Authors:  Alicja Ryta; Michal Chmielewski; Alicja Debska-Slizien; Piotr Jagodzinski; Malgorzata Sikorska-Wisniewska; Monika Lichodziejewska-Niemierko
Journal:  Int Urol Nephrol       Date:  2017-01-05       Impact factor: 2.370

5.  The association of erythropoietin-stimulating agents and increased risk for AV-fistula dysfunction in hemodialysis patients. A retrospective analysis.

Authors:  Anna Wärme; Henrik Hadimeri; Salmir Nasic; Bernd Stegmayr
Journal:  BMC Nephrol       Date:  2021-01-18       Impact factor: 2.388

6.  Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.

Authors:  Sunil V Badve; Lei Zhang; Jeff S Coombes; Elaine M Pascoe; Alan Cass; Philip Clarke; Paolo Ferrari; Stephen P McDonald; Alicia T Morrish; Eugenie Pedagogos; Vlado Perkovic; Donna Reidlinger; Anish Scaria; Rowan Walker; Liza A Vergara; Carmel M Hawley; David W Johnson
Journal:  Can J Kidney Health Dis       Date:  2015-08-18

Review 7.  Anaemia of Chronic Disease: An In-Depth Review.

Authors:  Anazoeze Jude Madu; Maduka Donatus Ughasoro
Journal:  Med Princ Pract       Date:  2016-09-28       Impact factor: 1.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.